Early experience Impella percutaneous ventricular assist device complications from a multi-ethic asian cohort
Background/ Purpose: Complications during percutaneous ventricular assist device (pVAD) use can be fatal. From our pVAD registry, we evaluate the complications encountered at an Asian tertiary heart centre. Methods: We performed an observational registry, evaluating complications from Impella...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/47088/1/European%20J%20of%20Heart%20Fail%20-%202024.pdf http://ir.unimas.my/id/eprint/47088/ https://onlinelibrary.wiley.com/toc/18790844/current |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background/ Purpose:
Complications during percutaneous ventricular assist device (pVAD) use can be fatal. From our pVAD registry, we evaluate the complications encountered at an Asian tertiary heart centre.
Methods: We performed an observational registry, evaluating complications from Impella CP pVAD use from 2019 to 2023, involving patients with cardiogenic shock (CS) or high-risk percutaneous coronary intervention (HR-PCI). Complications were stratified by initial (year 2019-2021) and later (year 2022-2023) implantation experience. Device related complications include access side bleeding, infection, haemolysis, limb ischemia, vascular injury, stroke, device failure, dislodge or exchange. Non-device related complications were defined as procedural or disease related complications.
Results: 30 patients were analysed, 36.7% had CS and 23% experienced in-hospital mortality. 57% of patients had complication during pVAD support, of which device related and non-device related complications incidences were 50% and 40%, respectively. Major access site bleeding was the most common device related complications (47%) and majority had BARC score of 2 and above. Non device related complications include requirement of vasopressors or inotropic support (40%), mechanical ventilation (37%) and renal replacement therapy (17%). In later stage of the registry, more pVAD therapies (60%) were delivered. More complete revascularization (22%), rotational atherectomy (11%) and concurrent VA-ECMO support was observed (22%). Access site bleeding incidence trended lower over time (58% vs 39%) while non-device related complications trended higher (33% vs 44%). In the later stage, more inotropy support (33% vs 44%) was given. CS cohort experienced more device (50% vs 67%) and non-device related complications (75% vs 100%) over time. In later stages, less HR-PCI cohort had device related complications (62.5% vs 33%). Lesser patients (75% vs 67%) with complications had in-patient mortality over time.
Conclusion: Access site bleeding is common in pVAD use. With experience, device related complications trended lower. The presence of sicker patients may explain increased non-device complications. |
|---|